-- TD銀行のマーク・エルコラオ氏は木曜日、カナダ経済は2025年第4四半期にGDPが縮小したものの、2026年には「堅調なスタートを切る見込みだ」と述べた。2月の統計と3月の速報値に基づくと、2026年第1四半期の成長率は約1.7%で推移しており、カナダ銀行が最近更新した経済予測および同行自身の予測と概ね一致していると指摘した。 「第1四半期以降の成長の推移は、短期的な勢いそのものよりも政策見通しにとって重要となるだろう。カナダ経済は、貿易をめぐる不確実性の高まりや、最近では中東紛争の影響など、様々な逆風に直面しているからだ」とエルコラオ氏は述べた。 「カナダ銀行は、これらの要因が経済見通しに両面的なリスクをもたらし、政策は依然としてデータに左右されると強調している。成長率やインフレ率が予想から大きく乖離した場合、政策理事会は対応する用意がある。とはいえ、我々の基本シナリオは、カナダ銀行が年内は政策金利を据え置くというものだ」とエルコラオ氏は付け加えた。 カナダの国内総生産(GDP)は2月に前月比0.2%増加し、カナダ統計局の速報値と市場の予想通りとなった。速報値では3月は成長なしと予測されており、卸売業と運輸業のさらなる成長は、小売業と鉱業、石油・天然ガス業の落ち込みによって相殺されるだろうとエルコラオ氏は指摘した。
Related Articles
Research Alert: Amgn Q1 Tops Estimates Driven By Diversified Growth And Pipeline Investments
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Amgen delivered solid Q1 2026 results with revenues of $8.6B (+6% Y/Y), $50M above consensus, and non-GAAP EPS of $5.15 (+5% Y/Y), beating expectations by $0.38. The company demonstrated continued execution of its portfolio diversification strategy, with sixteen products achieving double-digit growth and seventeen products annualizing above $1B. We favorably view AMGN's broad-based growth across newer therapeutic franchises, with standout performances from Repatha (+34% Y/Y), TEPEZZA (+29% Y/Y), and TEZSPIRE (+20% Y/Y), offsetting expected declines in legacy products facing biosimilar competition. Management raised 2026 guidance to $37.1B-$38.5B in revenues and EPS of $21.70-$23.10. R&D expenses surged 16% Y/Y to $1.7B, reflecting intensive investments in the MariTide obesity program and multiple Phase 3 studies. We believe AMGN's successful portfolio transformation and strategic focus on high-growth therapeutic areas position it well for sustained long-term growth.
Research Alert: Illumina: Sequencing Sales Growth Supports Q1 Eps Beat, Guidance Increased
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Illumina reported Q1 2026 adjusted EPS of $1.15, up 18.6% Y/Y and beating the $1.05 consensus estimate, while revenue grew 4.8% to $1.091B. Operating leverage was evident, with adjusted operating margin expanding 150 bps Y/Y to 21.9% due to consumables growth of 4.3% to $726M and instruments up 8.3% to $118M. The instrument growth suggests continued NovaSeq X adoption momentum, while rest-of-world organic revenue growth of 3.5% indicates healthy demand outside of China (declined 29% organically). ILMN raised full-year guidance, increasing revenue expectations by $20M at the midpoint to $4.52B-4.62B and adjusted EPS to $5.15-5.30 from $5.05-5.20. We view the recently-completed SomaLogic acquisition positively, as it expands ILMN's addressable market into proteomics and strengthens its multiomics portfolio. Strong cash generation was also present, with operating cash flow up 20.4% to $289M, supporting the newly-authorized $1.5B share repurchase program.
Research Alert: CFRA Lowers Opinion On Shares Of Bxp, Inc. From Hold To Sell
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We decrease our target by $10 to $51, 7.5x our 2026 FFO estimate as occupancy headwinds remain with large capex increases now planned to improve leasing. We lower our 2026 FFO forecast by $0.05 to $6.82 and 2027's by $0.22 to $7.03. BXP's most concerning headline in Q1 was the increase in capex planned to drive 2026 leasing going from $220M-$250M all the way up to $400M. In our view, this indicates that vacant properties likely need significant concessions to tenants or redevelopment spending from BXP to improve structurally impaired occupancy. Management believes BXP stock is attractive now but unable to repurchase due to high leverage, which we consider concerning given the weakness in leasing and negative re-leasing spreads. Leasing improved in Q1 in San Francisco, but remains negative in Boston/New York (BXP's largest CBD markets). We expect further disposition activity ($400M more this year) and share issuance in 2026, with the goal of reducing leverage.